New Patents iii

filtration is preferably done with a closed, ready- to-use system comprising a WBC filter disposed between a first blood bag and at least two empty secondary bags. A fourth bag may be included in the closed system to contain a platelet additive solution. System can remove at least 95% of the WBCs with less than 10% loss in platelets. In very preferred embodiments at least 99.5% of the original WBCs are removed by filtration prior to platelet storage.

5089494

4-PHENYLPHTHALAZINE DERIVATIVES WHICH INHIBIT

PLATELET AGGREGATION

Norimichi Iwase, Yasuhiro Morinaka, Yoshikuni Tamao, Toshiji Kanayama, Yokohama, Japan assigned to Mitsubishi Kasei Corporation

4-Phenylphthalazine derivatives having platelet aggregation inhibitory activity of the formula: See Patent for Chemical Structure wherein Rl is an alkyl or hydroxyalkyl group of l-5 carbon atoms; R2 is a hydrogen atom or an alkyl group of l-5 carbon atoms; or Rl and R2, when taken together, may represent an alkylene group of 2-6 carbon atoms, said group optionally containing one or more oxygen atoms; R3 and R4 are inde- pendently a hydrogen or halogen atom, an alkyl or alkoxy group of l-4 carbon atoms, or when two of R3 are adjacently positioned, (R3)l may represent a -O-(CHZ)p-O- group and/or when two of R4 are adjacently positioned, (R4)m may represent a -0-(CH2)p-O- group; R5 is a hydro- gen or halogen atom, an alkyl or alkoxy group of l-4 carbon atoms, a trifluoromethyl group or a hydroxy group, or when two of R5 are adja- cently positioned, (R5)n may represent a -O- (CH2)p-O- group; p is an integer of l-3; I and m are independently an integer of l-2; and n is an integer of l-3, and optical isomers and pharma- ceutically acceptable acid addition salts thereof.

5091302

POLYMORPHISM OF HUMAN PLATELET MEMBRANE

GLYCOPROTEIN IIIA AND DIAGNOSTIC AND

THERAPEUTIC APPLICATIONS THEREOF

Peter J Newman, Richard Aster assigned to The Blood Center of Southeastern Wisconsin Inc

Isolated polynucleotide molecules, and peptides encoded by those molecules, can be used in the analysis of alloantigen phenotypes, as well as in diagnostic and therapeutic applications relating to human platelet PIA polymorphism. In this vein, a method for typing blood cell and platelet membrane glycoproteins entails an analysis of amplified cDNA, encoded by platelet and red blood cell mRNA.

50913%

PYRIDYL PEPTIDE MIMETIC COMPOUNDS WHICH ARE

USEFUL PLATELET- AGGREGATION INHIBITORS

Foe Tjoeng, Steven Adams, Robert B Garland, Masater Miyano assigned to Monsanto Co; G D Searle & Co

Novel peptide mimetic compounds are provided which have useful activity as inhibitors of platelet aggregation. These compounds have the chemical structure See Patent for Chemical Structure wherein x = 4 to 8, y = 0 to 4, W = CH2- CH2 or C double bondCH, Z=H, COOH, CONH2, CH20H, C02R, CHZOR or Cl-6 alkyl, R=Ci-6 alkyl, Ar = a nitrogen- containing heterocyclic group, and Asp = aspar- tic acid residue.